

Medical Policy:

OmvoH (mirikizumab-mrkz) Intravenous infusion

POLICY NUMBER	LAST REVIEW	ORIGIN DATE
MG.MM.PH.408	January 18, 2024	March 28, 2024

Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved.

The treating physician or primary care provider must submit to EmblemHealth, or ConnectiCare, as applicable (hereinafter jointly referred to as “EmblemHealth”), the clinical evidence that the member meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request preauthorization or post-payment review. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. This clinical policy is not intended to pre-empt the judgment of the reviewing medical director or dictate to health care providers how to practice medicine. Health care providers are expected to exercise their medical judgment in rendering appropriate care. Health care providers are expected to exercise their medical judgment in rendering appropriate care.

EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary.

If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. Identification of selected brand names of devices, tests and procedures in a medical coverage policy is for reference only and is not an endorsement of any one device, test or procedure over another. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication.

EmblemHealth may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist us in administering health benefits. The MCG™ Care Guidelines are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice. EmblemHealth Services Company, LLC, has adopted this policy in providing management, administrative and other services to EmblemHealth Plan, Inc., EmblemHealth Insurance Company, EmblemHealth Services Company, LLC, and Health Insurance Plan of Greater New York (HIP) related to health benefit plans offered by these entities. ConnectiCare, an EmblemHealth company, has also adopted this policy. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definitions

OmvoH intravenous, a monoclonal antibody against the p19 subunit of the interleukin (IL)-23 cytokine, is indicated for induction treatment of ulcerative colitis (UC), in adults with moderate to severe active disease.

In UC, a three-dose induction regimen (300 mg at Weeks 0, 4, and 8) is administered by IV infusion.

Following induction therapy with the IV product, the recommended maintenance is OmvoH subcutaneous injection, given as a 200 mg subcutaneous injection administered at Week 12 (4 weeks following the last induction dose), then once every 4 weeks thereafter.

Length of Authorization

Coverage will be provided for 3 induction doses (600 mg at Weeks 0, 4, and 8)

Dosing Limits [Medical Benefit]

Max Units (per dose and over time) [HCPCS Unit]

Ulcerative Colitis: Induction dose: 300 billable units (300mg at Weeks 0, 4, and 8)

Guideline

I. INITIAL APPROVAL CRITERIA

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Physician has assessed baseline disease severity utilizing an objective measure/tool; **AND**
- Patient is up to date with all age-appropriate vaccinations, in accordance with current vaccination guidelines, prior to initiating therapy; **AND**
- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for the presence of TB during treatment; **AND**
- Patient does not have an active infection, including clinically important localized infections; **AND**
- Patient will not receive live vaccines during therapy; **AND**
- Patient is not on concurrent treatment with another IL-inhibitor, TNF-inhibitor, biologic response modifier or other non-biologic immunomodulating agent (e.g., apremilast, tofacitinib, baricitinib, upadacitinib, abrocitinib, deucravacitinib, etc.); **AND**
- Baseline liver enzymes and bilirubin levels have been obtained prior to initiating therapy; **AND**

Intravenous Induction Criteria:

1. Ulcerative Colitis

A. Documented moderate to severely active disease; **AND**

- i. Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of ONE corticosteroid or immunomodulator (e.g. azathioprine, 6-mercaptopurine, or methotrexate); **OR**
- ii. Documented failure, contraindication, or ineffective response at maximum tolerated doses to a minimum (3) month trial of a TNF modifier (e.g. adalimumab, certolizumab, or infliximab)

Applicable Procedure Codes

Code	Description
C9168	Injection, mirikizumab-mrkz, 1 mg; 1 billable unit = 1 mg (Effective 04/01/2024 for IV formulation ONLY)

Applicable NDCs

Code	Description
00002-7575-01	Omvoh IV infusion, single-dose vial 300mg/15ml (20mg/mL) carton of 1

ICD-10 Diagnoses

Code	Description
K00-K95	Diseases of the digestive system
K50-K52	Noninfective enteritis and colitis
K51	Ulcerative colitis

Revision History

Company(ies)	DATE	REVISION
EmblemHealth & ConnectiCare	3/28/2024	New Policy

References

1. Omvoh injection [prescribing information]. Indianapolis, IN: Eli Lilly; October 2023.
2. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114(3):384-413.
3. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. *Gastroenterology*. 2020 Apr158(5):1450-1461.